Skip to main content
    S

    Supernus Pharmaceuticals, Inc. (SUPN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $29.04
    +0.21 (+0.73%)

    Market Cap: $1.52B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Supernus Pharmaceuticals, Inc. (SUPN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Supernus Pharmaceuticals (SUPN) has a market cap of $1.52B and an enterprise value of $1.34B. Its trailing P/E of 12.8x is below its 10-year median of 54.9x. Revenue grew 24.85% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 11.81% below the market cap, as cash exceeds debt.

    Market Cap$1.52B
    Enterprise Value$1.34B
    Latest price (Nov 17, 2026)$29.04

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.73% in the quarter ended Jun 30, 2026 and grew 2.77% a year over 2 years.

    Shares Outstanding58.07M
    Shares Change (YoY)+3.65%
    Shares Change (QoQ)+0.73%
    Share Count Growth (2Y CAGR)+2.77%

    Valuation Ratios

    Sales and book value multiples are 2.0x and 1.6x. Its year-end P/E ranged from 12.6x to 158.1x from 2016 to 2025.

    P/E Ratio12.8x
    Forward P/E12.8x
    P/S Ratio2.0x
    Forward P/S1.1x
    P/B Ratio1.6x
    P/TBV Ratio3.8x
    P/FCF Ratio89.8x
    P/OCF Ratio76.5x
    PEG Ratio0.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 80.2x free cash flow.

    EV / Sales1.6x
    EV / FCF80.2x

    Price Statistics

    The stock is down 35.47% over 52 weeks and trades 5.45% above its 50-day average.

    Beta (1Y)0.54
    52-Week Change-35.47%
    1-Month Change+10.50%
    3-Month Change-4.13%
    6-Month Change-39.02%
    5-Year Change-76.30%
    10-Year Change-64.27%
    Total Return (1Y)-17.40%
    Total Return (3Y CAGR)+1.92%
    Total Return (5Y CAGR)-2.44%
    Return vs SPY (1Y)-46.88%
    Max Drawdown (1Y)-55.29%
    Max Drawdown (3Y)-55.83%
    Sharpe Ratio (1Y)-1.01
    Correlation with SPY (1Y)0.17
    50-Day Average$27.54
    200-Day Average$38.50
    52-Week Range$21.48 to $33.22
    RSI (14 Days)57.6
    Average Volume (20 Days)3.83M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.08x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.08x
    Quick Ratio1.84x
    Debt / Equity0.00x
    Interest Coverage2.15x

    Returns and Efficiency

    Return on equity is -10.66% over the last 12 months, against a 5-year average of 3.41%.

    Return on Equity (ROE)-10.66%
    Return on Assets (ROA)-7.69%
    Return on Capital Employed (ROCE)-11.42%
    ROE (5Y Average)3.41%
    ROA (5Y Average)1.92%
    ROIC (5Y Average)0.39%
    Asset Turnover0.59x
    Inventory Turnover1.16x
    Receivables Turnover4.22x
    Cash Conversion Cycle15 days

    Scores

    SUPN has an Altman Z-Score of 3.61, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score3.61
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $830.44M over the last 12 months.

    Revenue$830.44M
    Revenue Growth (YoY)+24.85%
    Gross Profit$731.41M
    Operating Income-$130.46M
    Pretax Income-$123.47M
    Net Income-$109.89M
    EBITDA-$22.72M
    EBIT-$123.47M
    Reported EPS (TTM)$2.26

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.03% of the $1.43B in total assets.

    Cash and Equivalents$179.95M
    Total Debt$0
    Net Cash$179.95M
    Net Cash Per Share$3.10
    Working Capital$376.12M
    Shareholder Equity$1.03B
    Book Value Per Share$17.76
    Tangible Book Value$442.34M
    Tangible Book Per Share$7.62
    Total Assets$1.43B
    Total Liabilities$396.88M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.12M of capital spending, operating cash flow left $18.79M of free cash flow.

    Operating Cash Flow$19.91M
    Capital Expenditures$1.12M
    Free Cash Flow$18.79M
    FCF Per Share$0.32
    Depreciation and Amortization$103.65M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -15.71%, against a 5-year average of 4.91%.

    Gross Margin88.07%
    Operating Margin-15.71%
    Pretax Margin-14.87%
    Net Margin-13.23%
    EBITDA Margin-2.74%
    EBIT Margin-14.87%
    FCF Margin2.26%
    Gross Margin (5Y Average)87.61%
    Operating Margin (5Y Average)4.91%
    Net Margin (5Y Average)4.87%

    Growth

    Revenue grew 2.52% a year over 3 years, and EPS 23.20% a year.

    Revenue Growth (3Y CAGR)+2.52%
    Revenue Growth (5Y CAGR)+6.68%
    EPS Growth (3Y CAGR)+23.20%
    EPS Growth (5Y CAGR)+3.79%
    FCF Growth (3Y CAGR)-26.62%
    FCF Growth (5Y CAGR)-19.34%
    Book Value Per Share Growth (2Y CAGR)+5.18%
    Tangible Book Per Share Growth (2Y CAGR)+31.30%

    Revenue and profit by year

    Dividends and Yields

    SUPN does not pay a dividend. Its free cash flow yield is 1.11%.

    Earnings Yield7.81%
    FCF Yield1.11%
    Buyback Yield-2.97%
    Shareholder Yield-2.97%

    Stock Splits

    The last split was a 1-for-5 reverse split on Oct 11, 2022.

    Last Split DateOct 11, 2022
    Split TypeReverse split
    Split Ratio1:5

    Peer Position

    Against 11 similar companies, SUPN has the 5th highest P/E.

    P/E Ratio12.8x vs 10.7x median
    P/S Ratio2.0x vs 2.0x median
    Revenue Growth (Trailing 4 Quarters, YoY)+24.85% vs +10.45% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 39.52% and EPS growth at 25.93% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+39.52%
    EPS Growth Forecast (2Y CAGR)+25.93%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SUPN

    What is SUPN's market cap?

    Supernus Pharmaceuticals has a market cap of $1.52B. Its enterprise value, which adds debt and subtracts cash, is $1.34B.

    What is SUPN's P/E ratio?

    Supernus Pharmaceuticals has a trailing P/E ratio of 12.8x and a forward P/E of 12.8x.

    How many shares of SUPN are outstanding?

    Supernus Pharmaceuticals has 58.07M shares outstanding. The count is up 3.65% from a year earlier.

    Does SUPN pay a dividend?

    No. Supernus Pharmaceuticals does not pay a dividend.

    How much debt does SUPN have?

    Supernus Pharmaceuticals has $0 of total debt and $179.95M of cash and equivalents, a net cash position of $179.95M.